Alkermes

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

—  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN , June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D.

Alkermes Appoints Caroline J. Loew, Ph.D.

DUBLIN , May 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences. Jefferies Healthcare Conference Date/Time: Wednesday, June 7, 2023 at 10:00 a.m.

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board's Independent Directors Have Been Appointed Over the Last Four Years, Including Four Directors Designated or Supported by Shareholders Company Launches www.AlkermesValue.com , Providing Additional Information for Shareholders Alkermes' Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHITE Proxy Card DUBLIN , May 25, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023. The letter details the Company's successful execution and value creation since the announcement of its Value Enhancement Plan in December 2020.

Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

̶  Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder  ̶ DUBLIN , May 16, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of these meetings coincide with Mental Health Awareness Month in May, an important moment in the year that provides an opportunity to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers who deliver care each day.

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences

–  Trial-in-Progress Posters From ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented – DUBLIN , May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented.

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

DUBLIN , May 8, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts.

Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process

LIVONIA, Mich.--(BUSINESS WIRE)-- #AI--Datamatics has entered into a strategic partnership with Alkermes.

Datamatics Partners with Alkermes to Help Support Patients

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

Alkermes plc (ALKS) Q1 2023 Earnings Call Transcript.

Alkermes plc (ALKS) Q1 2023 Earnings Call Transcript

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Alkermes (ALKS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.12 per share a year ago.

Alkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates

—  First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio — —  GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 — —  Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 — —  Second Favorable Interim Award Received in Janssen Arbitration — —  Financial Expectations for 2023 Reiterated — DUBLIN , April 26, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2023. "During the first quarter we made continued progress across our portfolio, including strong commercial execution driving growth for our proprietary products – LYBALVI®, VIVITROL® and ARISTADA® – and important progress in the development of ALKS 2680, our orexin 2 receptor agonist, which is now poised to enter a phase 1b proof-of-concept study in patients with narcolepsy and idiopathic hypersomnia, with data expected later this year," said Richard Pops, Chief Executive Officer of Alkermes.

Alkermes plc Reports First Quarter 2023 Financial Results

DUBLIN , April 25, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.

Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

DUBLIN , April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

Alkermes to Report First Quarter Financial Results on April 26, 2023

– Application Period to Begin on May 1, 2023 – DUBLIN , April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on May 1, 2023. Now in its seventh year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.

Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential draft Form 10 registration statement to the United States Securities and Exchange Commission in connection with the previously announced planned separation of the company's oncology business into an independent, publicly-traded company (Oncology Co.). The company continues to expect to complete the separation in the second half of 2023.

Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business

Alkermes' recent clinical trial results for Lybalvi demonstrate a promising treatment option for young adults with schizophrenia or bipolar I disorder who are early in the progression of their illness. The combination of olanzapine and samidorphan in Lybalvi may reduce olanzapine-induced weight gain, a common side effect in patients with these conditions.

Alkermes' Strong Pipeline Positions It For Future Growth

DUBLIN , March 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI® (olanzapine and samidorphan) in the peer-reviewed publication, the Journal of Clinical Psychiatry. ENLIGHTEN-Early evaluated the effect of LYBALVI compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness.

Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness

DUBLIN , March 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 9:00 a.m. ET (2:00 p.m.

Alkermes to Participate in the Stifel 2023 CNS Days

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

Alkermes plc (NASDAQ:ALKS ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Todd Nichols - Chief Commercial Officer Iain Brown - Chief Financial Officer Richard Pops - Chief Executive Officer Conference Call Participants David Amsellem - Piper Sandler Akash Tiwari - Jeffries Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs Paul Matteis - Stifel Uy Ear - Mizuho Jason Gerberry - Bank of America Jessica Fye - J.P. Morgan Marc Goodman - SVB Douglas Tsao - H.C.

Alkermes plc (ALKS) Q4 2022 Earnings Call Transcript

Seagen

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared. The post Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out appeared first on Investor's Business Daily.

Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out

Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Alkermes Stock (ALKS)